Sarver Heart Cemter, Room 4137
High Throughput Kinetic Studies of iPSC-Cardiomyocyte: Bringing the Patient Context to Early Stage Drug Discovery
Mark Mercola, PhD
Professor,
Stanford Cardiovascular Institute and the Department of Medicine,
Stanford University
Dr. Mercola is Professor of Cardiovascular Medicine at Stanford University and a member of the Stanford Cardiovascular Institute. He completed postdoctoral training at the Dana-Farber Cancer Institute and Harvard Medical School. He was an Assistant and Associate Professor of Physiology at Harvard Medical School and relocated to California in 2003 where he was Professor of Bioengineering at the University of California, San Diego and jointly at the Sanford-Burnham-Prebys Medical Research Institute. At Sanford-Burham-Prebys, he co-founded the Prebys Center for Drug Discovery.
He serves on multiple editorial and advisory boards, including Vala Sciences (San Diego) and The Ted Rogers Cardiovascular Institute (Toronto). His laboratory is funded by the National Institutes of Health, the California Institute for Regenerative Medicine and the Fondation Leducq. Dr. Mercola is best known for discovering molecules that induce heart formation and for iPSC-based disease modeling for cardiovascular drug target discovery and drug development.